Percutaneous aortic valve replacement

Pi-Cardia Successfully Treats First Patients with ShortCut™ Device

Retrieved on: 
Thursday, January 7, 2021
Biotechnology, Health, Cardiology, Medical devices, Medical specialties, Medicine, Clinical medicine, Cardiac surgery, Cardiology, Prosthetics, Aortic valve replacement, Aortic valve, Aortic stenosis, Percutaneous aortic valve replacement, Stenosis, Heart valve

ShortCut is the worlds first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary obstruction or compromised coronary access.

Key Points: 
  • ShortCut is the worlds first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary obstruction or compromised coronary access.
  • Using ShortCut we were able to treat two extremely complex patients with degenerated valves that needed a solution to prevent coronary obstruction after TAVR.
  • ShortCut is the latest addition to Pi-Cardias product offering, which includes the Leaflex device a standalone, non-implant-based treatment for patients with aortic stenosis.
  • As the number of patients with aortic stenosis continues to grow, both Shortcut and Leaflex may offer important new treatment options for both physicians and patients.

Extended FEops HEARTguide™ Offering Now Available

Retrieved on: 
Friday, December 18, 2020
Cardiology, Software, Biotechnology, Surgery, Health, Medical devices, Technology, Other Health, Anatomy, Circulatory system, Heart, Aortic valve, Bicuspid aortic valve, Percutaneous aortic valve replacement, Heart valve, Cardiac surgery, Cardiology, Aortic valve replacement

FEops , a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce the new release of FEops HEARTguideTM.

Key Points: 
  • FEops , a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce the new release of FEops HEARTguideTM.
  • With this release, FEops HEARTguide continues to focus on complex anatomies in the TAVI workflow with further enhancements to the modelling of patients with a bicuspid aortic valve.
  • Promising data on 19 patients with bicuspid aortic valve treated using FEops HEARTguide was presented last month at the PCR Valves e-Course 2020.
  • In December 2019, FEops has been awarded a grant of Euro 3.2million from the European Innovation Council (EIC) accelerator programme.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors

Retrieved on: 
Monday, December 7, 2020
Legal, Professional services, Cardiac surgery, Medical specialties, Medicine, Anatomy, Boston Scientific, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic valve, New York Stock Exchange, Heart valve, Valve replacement, BSX

Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (Boston Scientific or the Company) (NYSE: BSX ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (Boston Scientific or the Company) (NYSE: BSX ) investors concerning the Companys possible violations of federal securities laws.
  • On November 17, 2020, Boston Scientific announced a worldwide recall of all unused inventory of the LOTUS Edge Aortic Valve System, a transcatheter aortic valve replacement product which had been approved by the U.S. Food and Drug Administration (FDA) in April 2019.
  • On this news, Boston Scientific's stock price fell $3.00 per share, or approximately 8%, to close at $35.03 per share on November 17, 2020, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Global Aortic Valve Market Research Report 2020: Valve Type (Tissue/Biological, Mechanical), Suture Type (Sutured, Sutureless), Procedure (Open Surgery, Minimally Invasive Surgery) - ResearchAndMarkets.com

Retrieved on: 
Friday, November 13, 2020
Surgery, Health, Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve, Aortic stenosis, Valve replacement, Heart valve, Aortic valve repair, Percutaneous aortic valve replacement

The "Aortic Valve Market Research Report: By Valve Type (Tissue/Biological, Mechanical), Suture Type (Sutured, Sutureless), Procedure (Open Surgery, Minimally Invasive Surgery), End User (Hospitals, Ambulatory Surgery Centers) - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aortic Valve Market Research Report: By Valve Type (Tissue/Biological, Mechanical), Suture Type (Sutured, Sutureless), Procedure (Open Surgery, Minimally Invasive Surgery), End User (Hospitals, Ambulatory Surgery Centers) - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • When procedure is taken into consideration, the aortic valve market is divided into open surgery and minimally invasive surgery (MIS), between which, the MIS division held the major value share of the market in 2019.
  • Some of the common treatments recommended for aortic stenosis are transcatheter aortic valve treatment and surgical valve replacement.
  • Companies operating in the aortic valve market are focusing widely on business mergers, strategic partnerships, product launches, and trial and approvals for remaining competitive in the domain.

OrbusNeich® Medical and P+F Products & Features® announce new partnership

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Medicine, Clinical medicine, Cardiac surgery, Valvular heart disease, Aortic stenosis, Aortic valve, Cardiology, Percutaneous aortic valve replacement, Stenosis, Aortic valve replacement

The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.

Key Points: 
  • The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.
  • The minimally invasive valve replaces the native aortic valve without the need for concomitant surgical removal.Both systemsare pending CE mark approval.
  • "This powerful partnership supports our strategic business directive to add important complementary structural heart devices to our coronary and peripheral portfolio.
  • OrbusNeich supplies medical devices to physicians in more than 60 countries.

OrbusNeich® Medical and P+F Products & Features® announce new partnership

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Medicine, Clinical medicine, Cardiac surgery, Valvular heart disease, Aortic stenosis, Aortic valve, Cardiology, Percutaneous aortic valve replacement, Stenosis, Aortic valve replacement

The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.

Key Points: 
  • The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.
  • The minimally invasive valve replaces the native aortic valve without the need for concomitant surgical removal.Both systemsare pending CE mark approval.
  • "This powerful partnership supports our strategic business directive to add important complementary structural heart devices to our coronary and peripheral portfolio.
  • OrbusNeich supplies medical devices to physicians in more than 60 countries.

Sirtex Medical appoints Francis Jannot as Executive Vice President of International Sales

Retrieved on: 
Tuesday, October 6, 2020
Anatomy, Radiation therapy, Sirtex, Aortic valve, Heart valve, Percutaneous aortic valve replacement, Boston Scientific

WOBURN, Mass., Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.

Key Points: 
  • WOBURN, Mass., Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.
  • Under Mr. Jannot's leadership, the implementation of best-in-class sales processes and both organic and inorganic growth in international marketing will be leading areas of focus.
  • Prior to joining Sirtex, Mr. Jannot worked for Boston Scientific, where he served as Vice President of Global Commercial Operations for the structural heart valves business unit.
  • Prior to working for Boston Scientific, Francis was Vice President of Sales and Marketing Europe at Symetis, a start-up dedicated to the transcatheter aortic valve implantation market.

Sirtex Medical appoints Francis Jannot as Executive Vice President of International Sales

Retrieved on: 
Tuesday, October 6, 2020
Anatomy, Radiation therapy, Sirtex, Aortic valve, Heart valve, Percutaneous aortic valve replacement, Boston Scientific

WOBURN, Massachusetts, Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.

Key Points: 
  • WOBURN, Massachusetts, Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.
  • Under Mr. Jannot's leadership, the implementation of best-in-class sales processes and both organic and inorganic growth in international marketing will be leading areas of focus.
  • Prior to joining Sirtex, Mr. Jannot worked for Boston Scientific, where he served as Vice President of Global Commercial Operations for the structural heart valves business unit.
  • Prior to working for Boston Scientific, Francis was Vice President of Sales and Marketing Europe at Symetis, a start-up dedicated to the transcatheter aortic valve implantation market.

JenaValve Technology Appoints Peter L. Spadaro Chief Commercial Officer

Retrieved on: 
Monday, September 28, 2020
Health, Clinical trials, Cardiology, Medical devices, Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic valve, Valve replacement, Heart valve, Aortic stenosis, Lexington Medical Center, the JenaValve Transfemoral TAVR System, JenaValve

JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Peter L. Spadaro, Jr. to the newly created position of Chief Commercial Officer.

Key Points: 
  • JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Peter L. Spadaro, Jr. to the newly created position of Chief Commercial Officer.
  • He brings us unrivaled industry experience including a stellar track record in commercial planning and tactical execution.
  • Peter has the ability to identify and capitalize on market opportunities and brings to JenaValve long established relationships with cardiovascular key opinion leaders and practitioners worldwide.
  • JenaValve Technology, Inc., with locations in Irvine, California, Leeds, U.K. and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease.

VitalConnect Announces Initiation of TELESTAR-TAVR Clinical Study

Retrieved on: 
Wednesday, September 16, 2020
Mobile, Wireless, Technology, Medical devices, Hospitals, Clinical trials, Telecommunications, Software, Biotechnology, Hardware, Health, Medicine, Medical specialties, Clinical medicine, Cardiac surgery, Percutaneous aortic valve replacement, Cardiology, Aortic valve replacement, Valve replacement, Aortic valve, Clinical trial, Telehealth

VitalConnect, Inc. , a leader in remote and in-hospital wearable biosensor technology, announced today that it has begun the TELESTAR-TAVR clinical study (Deployment of Telemedicine for Symptom Tracking And Decrease Readmission Rate in TAVR Patients).

Key Points: 
  • VitalConnect, Inc. , a leader in remote and in-hospital wearable biosensor technology, announced today that it has begun the TELESTAR-TAVR clinical study (Deployment of Telemedicine for Symptom Tracking And Decrease Readmission Rate in TAVR Patients).
  • The TELESTAR-TAVR Study will evaluate patients who undergo a transcatheter aortic valve replacement (TAVR) and monitor them following the procedure utilizing the latest technology from VitalConnect, VistaSolution LIVE.
  • This information may aid providers to monitor early signs of deterioration, predict possible complications, and adjust treatment strategy to optimize clinical outcomes.
  • Were looking forward to the results of this study and the impact that RPM may have on optimizing clinical outcomes and increasing patient satisfaction following TAVR.